-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MCLA-129 in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MCLA-129 in Laryngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MCLA-129 in Laryngeal Cancer Drug Details: MCLA-129 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MCLA-129 in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MCLA-129 in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MCLA-129 in Oropharyngeal Cancer Drug Details: MCLA-129 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MCLA-129 in Paranasal Sinus And Nasal Cavity Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MCLA-129 in Paranasal Sinus And Nasal Cavity Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MCLA-129 in Paranasal Sinus And Nasal Cavity Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rucaparib Camsylate in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rucaparib Camsylate in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rucaparib Camsylate in Metastatic Pancreatic Cancer Drug Details: Rucaparib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Petosemtamab in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Petosemtamab in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Petosemtamab in Head And Neck Squamous Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INCA-32459 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INCA-32459 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INCA-32459 in Head And Neck Squamous Cell...
-
Product Insights
Anal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Anal Cancer - Drugs In Development, 2023’, provides an overview of the Anal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Salivary Gland Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Salivary Gland Cancer - Drugs In Development, 2023’, provides an overview of the Salivary Gland Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Salivary Gland Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Vulvar Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Vulvar Cancer - Drugs In Development, 2023’, provides an overview of the Vulvar Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vulvar Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...